Creso Pharma Management

Management criteria checks 1/4

Creso Pharma's CEO is Will Lay, appointed in Jan 2022, has a tenure of 1.08 years. directly owns 0.63% of the company’s shares, worth A$199.35K. The average tenure of the management team and the board of directors is 4.1 years and 1.2 years respectively.

Key information

Will Lay

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.1yrs
CEO ownership	0.6%
Management average tenure	4.1yrs
Board average tenure	1.2yrs

Recent management updates

Recent updates

CEO

Will Lay

1.1yrs

Tenure

Mr. William Lay, also known as Will, B.Com (Hons.) serves as Group Chief Executive Officer, Managing Director and Director at Creso Pharma Limited since January 17, 2022 and served as its Executive Vice Pr...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Boaz Wachtel	Co-Founder & Non-Executive Chairman	7.3yrs	AU$167.14k	0.10% A$ 31.9k
Christopher Grundy	Chief Financial Officer	5.3yrs	AU$501.65k	0.047% A$ 15.0k
William Lay	Group CEO	1.1yrs	no data	0.63% A$ 199.4k
Gian Trepp	Commercial & Marketing Director	4.1yrs	no data	no data
Micheline MacKay	MD & Executive Director	1.1yrs	no data	no data
Jodi Scott	Executive Director & President of US Operations	less than a year	no data	10.48% A$ 3.3m
Erlyn Dawson	Joint Company Secretary	4.3yrs	no data	no data
Winton Willesee	Joint Company Secretary	4.3yrs	no data	no data
Simon H. Buckingham	Consultant	5.7yrs	AU$18.38k	no data
Brian Walker	Strategic Consultant & Chair of Scientific Advisory Committee	1.3yrs	no data	no data

4.1yrs

Average Tenure

60yo

Average Age

Experienced Management: CPHOA's management team is considered experienced (4.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Boaz Wachtel	Co-Founder & Non-Executive Chairman	7.3yrs	AU$167.14k	0.10% A$ 31.9k
William Lay	Group CEO	1.1yrs	no data	0.63% A$ 199.4k
Micheline MacKay	MD & Executive Director	1.1yrs	no data	no data
Jodi Scott	Executive Director & President of US Operations	less than a year	no data	10.48% A$ 3.3m
Brian Walker	Strategic Consultant & Chair of Scientific Advisory Committee	1.3yrs	no data	no data
Walter Von Wartburg	Member of Scientific Advisory Board	4.1yrs	no data	no data
Bruce Linton	Independent Non-Executive Director & Strategic Advisor	2.3yrs	no data	0.52% A$ 166.1k
Isaac Kobrin	Member of Scientific Advisory Board	no data	no data	no data
Felix Gutzwiller	Member of Scientific Advisory Board	5.9yrs	no data	no data
Peter Hatfull	Non-Executive Director	less than a year	no data	no data
Ben Quirin	Non-Executive Director	less than a year	no data	no data

1.2yrs

Average Tenure

71.5yo

Average Age

Experienced Board: CPHOA's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.

Creso Pharma Management

Management criteria checks 1/4

Key information

Recent management updates

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

Melodiol Global Health Limited Announces Resignation of Erlyn Dawson as Joint Company Secretary

Creso Pharma Limited Announces Board Changes

Creso Pharma Limited Announces Director Appointments

Creso Pharma Limited Announces Board Changes

Creso Pharma Limited, Annual General Meeting, May 31, 2022

Recent updates

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.

Melodiol Global Health Limited Option Expiring 13 November 2028 Deferred Settlement Deleted from OTC Equity

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215 million.

Melodiol Global Health Limited Announces Resignation of Erlyn Dawson as Joint Company Secretary

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 0.231808 million.

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 1.022261 million.

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 1.022261 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 1.010906 million.

Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million.

Creso Pharma Limited (ASX:CPH) entered into a binding letter of intent to acquire Abby & Finn, LLC for $2.5 million.

Creso Pharma Limited Announces Board Changes

Creso Pharma Limited Announces Director Appointments

Creso Pharma Limited Announces Board Changes

Sierra Sage Secures USD 214,000 Purchase Order from Walmart

Creso Pharma Limited (ASX:CPH) signed a non-binding, non-exclusive heads of agreement to acquire Dr Pickles Pty Ltd.

Creso Pharma Limited, Annual General Meeting, May 31, 2022

Creso Pharma Limited announced that it expects to receive AUD 5 million in funding

Creso Pharma to Develop New Hemp-Based Lozenge Product

Creso Pharma Limited Launches New E-Commerce Channels

Creso Pharma Limited (ASX:CPH) completed the acquisition of Halucenex Life Sciences Inc.

Creso Pharma Limited Launches New Product

Creso Pharma Limited (ASX:CPH) entered into an agreement to acquire Halucenex Life Sciences Inc. CAD 10 million.

Creso Pharma Limited Signs Non-Binding Letter of Intent with ImpACTIVE Holdings Ltd

Creso Pharma Limited Executes A Non-Binding Letter of Intent with Ceres Natural Remedies

Creso Pharma Limited Revises Earnings Guidance for the Fiscal Year 2021

Creso Pharma Limited Announces Distribution Agreement with Route2 Pharm Pvt Ltd

CBD Oil legal in Australia - Creso Pharma Limited to benefit

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age